Stock in AbbVie slipped immediately after the drug organization noted a increased income than envisioned, when product sales fell limited.
The revenue shortfall could have reminded traders of a challenge
AbbVie
(ticker: ABBV) faces upcoming yr, when patent protection on its blockbuster arthritis drug Humira expires, enabling for the competitiveness from generic variations. Humira, the best-advertising drug in professional medical record, has achieved once-a-year income of $20.7 billion.
Stock in AbbVie slipped immediately after the drug organization noted a increased income than envisioned, when product sales fell limited.
The revenue shortfall could have reminded traders of a challenge
AbbVie
(ticker: ABBV) faces upcoming yr, when patent protection on its blockbuster arthritis drug Humira expires, enabling for the competitiveness from generic variations. Humira, the best-advertising drug in professional medical record, has achieved once-a-year income of $20.7 billion.
